A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
11/22/2023
Locations: Windsor Dermatology dba Eczema Treatment Center of New Jersey, East Windsor, New Jersey
Conditions: Atopic Dermatitis
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Recruiting
The co-primary objectives of the study are to: Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD). Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema Area and Severity Index (EASI).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/22/2023
Locations: Weiss Medical, Riverdale, New Jersey
Conditions: Atopic Dermatitis
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/15/2023
Locations: Continental Clinical Solutions - Cherry Hill, Cherry Hill, New Jersey
Conditions: Atopic Dermatitis
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Recruiting
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Schweiger Dermatology Group, Hackensack, New Jersey
Conditions: Atopic Dermatitis
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The coprimary objectives of the study are to: evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™). evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/15/2023
Locations: Schweiger Dermatology Group, PC Research Division, Hackensack, New Jersey
Conditions: Atopic Dermatitis
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
Recruiting
Phase 2 study of RPT193 in adults with atopic dermatitis
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/14/2023
Locations: Schweiger Dermatology Group, Verona, New Jersey
Conditions: Atopic Dermatitis
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
10/20/2023
Locations: Windsor Dermatology, East Windsor, New Jersey +1 locations
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Recruiting
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/18/2023
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Atopic Dermatitis
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Recruiting
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
09/19/2023
Locations: Rao Dermatology, Atlantic Highlands, New Jersey
Conditions: Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
Recruiting
This is a two-part, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral difelikefalin as adjunct therapy to a topical corticosteroid (TCS) for moderate-to-severe pruritus in adult subjects with atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2023
Locations: Cara Therapeutics Study Site, Hackensack, New Jersey
Conditions: Pruritus, Atopic Dermatitis